[go: up one dir, main page]

WO2000006769A3 - Human ccr-2 gene polymorphisms - Google Patents

Human ccr-2 gene polymorphisms Download PDF

Info

Publication number
WO2000006769A3
WO2000006769A3 PCT/GB1999/002341 GB9902341W WO0006769A3 WO 2000006769 A3 WO2000006769 A3 WO 2000006769A3 GB 9902341 W GB9902341 W GB 9902341W WO 0006769 A3 WO0006769 A3 WO 0006769A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccr
gene
polymorphisms
gene polymorphisms
human ccr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/002341
Other languages
French (fr)
Other versions
WO2000006769A2 (en
Inventor
John Craig Smith
Rakesh Anand
John Edward Norris Morten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9816193.8A external-priority patent/GB9816193D0/en
Priority claimed from GBGB9901844.2A external-priority patent/GB9901844D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Priority to AU50529/99A priority Critical patent/AU5052999A/en
Priority to JP2000562551A priority patent/JP2002521063A/en
Priority to EP99934896A priority patent/EP1100963A2/en
Publication of WO2000006769A2 publication Critical patent/WO2000006769A2/en
Publication of WO2000006769A3 publication Critical patent/WO2000006769A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to polymorphisms in the human CCR-2 gene, in particular to the discovery of two polymorphisms in the coding sequence of the CCR-2 gene and 11 polymorphisms in the promoter sequence of the CCR-2 gene. The invention also relates to methods and materials for analysing allelic variation in the CCR-2 gene, and to the use of CCR-2 polymorphism in the diagnosis and treatment of CCR-2 ligand mediated diseases such as rheumatoid arthritis and other inflammatory diseases.
PCT/GB1999/002341 1998-07-25 1999-07-20 Human ccr-2 gene polymorphisms Ceased WO2000006769A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU50529/99A AU5052999A (en) 1998-07-25 1999-07-20 Human ccr-2 gene polymorphisms
JP2000562551A JP2002521063A (en) 1998-07-25 1999-07-20 Human CCR-2 gene polymorphism
EP99934896A EP1100963A2 (en) 1998-07-25 1999-07-20 Human ccr-2 gene polymorphisms

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9816193.8A GB9816193D0 (en) 1998-07-25 1998-07-25 Chemical compounds
GB9816193.8 1998-07-25
GB9901844.2 1999-01-28
GBGB9901844.2A GB9901844D0 (en) 1999-01-28 1999-01-28 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2000006769A2 WO2000006769A2 (en) 2000-02-10
WO2000006769A3 true WO2000006769A3 (en) 2000-05-11

Family

ID=26314110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002341 Ceased WO2000006769A2 (en) 1998-07-25 1999-07-20 Human ccr-2 gene polymorphisms

Country Status (4)

Country Link
EP (1) EP1100963A2 (en)
JP (1) JP2002521063A (en)
AU (1) AU5052999A (en)
WO (1) WO2000006769A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100890448B1 (en) 2001-03-30 2009-03-26 시오자와 순이찌 Genome DNA involved in chronic arthritis, diagnostic methods thereof, methods for determining their probabilities, and diagnostic kits for their detection

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004183D0 (en) * 2000-02-22 2000-04-12 Smithkline Beecham Plc New use
DE10049549A1 (en) * 2000-10-06 2002-05-02 Markus Hecker Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40
RU2180922C1 (en) * 2001-03-14 2002-03-27 Ромащенко Аида Герасимовна Method of assay of chemokine receptor ccr2 gene alleles at polymorphous site v64i
US7306913B2 (en) 2002-12-20 2007-12-11 Applera Corporation Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09238688A (en) * 1996-03-11 1997-09-16 Takeda Chem Ind Ltd Production of human mcp-1 receptor protein and its use
WO1997040462A2 (en) * 1996-04-19 1997-10-30 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
US5707815A (en) * 1994-01-13 1998-01-13 Regents Of The University Of California Mammalian monocyte chemoattractant protein receptors and assays using them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707815A (en) * 1994-01-13 1998-01-13 Regents Of The University Of California Mammalian monocyte chemoattractant protein receptors and assays using them
JPH09238688A (en) * 1996-03-11 1997-09-16 Takeda Chem Ind Ltd Production of human mcp-1 receptor protein and its use
WO1997040462A2 (en) * 1996-04-19 1997-10-30 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ANZALA A O ET AL.: "CCR2-64I allele and genotype association with delayed AIDS progression in african women", THE LANCET, vol. 351, 1998, pages 1632 - 1633, XP002121127 *
DATABASE GENBANK 1995, HILLIER L ET AL.: "The WashU-Merck EST project", XP002131229 *
DATABASE GENBANK 1997, WONG L M ET AL.: "Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene" *
KOSTRIKIS ET AL: "A chemokine receptor CCR2 allele delays HIV -1 disease progression is associated with a CCR5 promoter mutation", NATURE MEDICINE, vol. 4, no. 3, March 1998 (1998-03-01), pages 350 - 353, XP002099017, ISSN: 1078-8956 *
MUMMIDI S ET AL.: "Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression", NATURE MEDICINE, vol. 4, no. 7, 1998, pages 786 - 793, XP002121126 *
NEWTON C R ET AL: "ANALYSIS OF ANY POINT MUTATION IN DNA. THE AMPLIFICATION REFRACTORY MUTATION SYSTEM (ARMS)", NUCLEIC ACIDS RESEARCH, vol. 17, no. 7, 11 April 1989 (1989-04-11), pages 2503 - 2516, XP000141596, ISSN: 0305-1048 *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 01 30 January 1998 (1998-01-30) *
RIZZARDI G P ET AL.: "CCR2 polymorphism and HIV disease", NATURE MEDICINE, vol. 4, no. 3, 1998, pages 252 - 253, XP002121128 *
SMITH ET AL: "Contrasting genetic influence of CCR2 and CCR5 variants on HIV -1 infection and disease progression", SCIENCE, vol. 277, 15 August 1997 (1997-08-15), pages 959 - 965, XP002099015, ISSN: 0036-8075 *
SOZZANI S ET AL: "MCP -1 and CCR2 in HIV infection: regulation of agonist and receptor expression", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 62, July 1997 (1997-07-01), pages 30 - 33, XP002099019, ISSN: 0741-5400 *
WONG L-M ET AL.: "Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 2, 1997, pages 1038 - 1045, XP002121129 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100890448B1 (en) 2001-03-30 2009-03-26 시오자와 순이찌 Genome DNA involved in chronic arthritis, diagnostic methods thereof, methods for determining their probabilities, and diagnostic kits for their detection

Also Published As

Publication number Publication date
JP2002521063A (en) 2002-07-16
EP1100963A2 (en) 2001-05-23
AU5052999A (en) 2000-02-21
WO2000006769A2 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
GB2342717A (en) Methods for analyzing ltc4 synthase polymorphisms and diagnostic use
CA2000786A1 (en) 3-piperidinyl-1,2-benzisoxazoles
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
CA2295999A1 (en) Nik proteins, nucleic acids and methods
EP0897390A4 (en)
CA2002868A1 (en) Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO2000073469A3 (en) Protein kinases
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO1999051727A3 (en) Human nucleic acid sequences of normal ovary tissue
CA2281895A1 (en) Ikb kinases
EP1589115A3 (en) Polymorphisms of the human organic anion transporting polypeptide-C (OATP-C)
WO2000053749A3 (en) Vascular adhesion molecules and modulation of their function
DE69816467D1 (en) ROBO: A FAMILY OF POLYPEPTIDES AND NUCLEIC ACIDS EFFECTIVELY IN NERVOUS LINE
EP1130123A3 (en) Diagnostic method
EP1005539A4 (en) IKK-$g(a) PROTEINS, NUCLEIC ACIDS AND METHODS
WO2001042474A3 (en) Interferon-like molecules and uses thereof
EP1203827A3 (en) Polymorphisms in the human KDR gene
WO2000006769A3 (en) Human ccr-2 gene polymorphisms
CA2495529A1 (en) Noonan syndrome gene
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia
WO2003054167A3 (en) Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
EP1130122A3 (en) Methods for the diagnosis of polymorphisms in the human EP1-R gene
WO1998033937A3 (en) GENOMIC SEQUENCE OF THE HUMAN ν-OPIOID RECEPTOR GENE AND THE VARIANTS, POLYMORPHISMS AND MUTATIONS THEREOF
WO2002046458A3 (en) Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof
WO2002072632A3 (en) Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999934896

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09720531

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 562551

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999934896

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999934896

Country of ref document: EP